GRUV, Universal’s relatively new DVD site, has put a bunch of digital copies on sale for $9.99 or less, with many up for only ...

Analysts See Growth at Yum! Brands Units. In naming Yum! Brands one of its top picks, Oppenheimer analysts said that the ...

Oppenheimer raised the firm’s price target on Atlassian (TEAM) to $300 from $270 and keeps an Outperform rating on the shares ...

Oppenheimer downgraded BJ’s Restaurants (BJRI) to Perform from Outperform. The company’s underlying fundamentals appear solid, but the firm ...

Apple / Universal. When Killers Of The Flower Moon first released in theaters and then later on Apple TV, I found the runtime ...

Robert Oppenheimer in "Oppenheimer." After spending six months getting ready both physically and mentally, he says he put all ...

Christopher Nolan's next film 'The Odyssey' is a mythic action epic shot across the world using brand new IMAX film ...

Colin Rusch, Oppenheimer senior research analyst, joins 'Squawk Box' to discuss Tesla's deliveries data, Musk's relationship ...

Oppenheimer analyst Kristen Owen maintained a Hold rating on Mosaic Co (MOS – Research Report) today. The company’s shares closed last Friday ...

The 2025 winners were all over the map, portending a wide-open awards season.

周三，Oppenheimer重申了对Catalyst Pharmaceutical Partners (NASDAQ:CPRX)股票的"跑赢大盘"评级，目标价保持在29.00美元。这一积极展望是在Catalyst Pharmaceutical宣布与TEVA就Firdapse仿制药营销达成交割协议之后做出的。

周三，Oppenheimer重申了对Jasper Therapeutics (NASDAQ:JSPR)的"优于大市"评级和80.00美元的目标价，此举是在该公司报告了其BEACON研究的初步结果之后。这家市值约18亿美元的临床阶段生物技术公司正在开发用于治疗慢性疾病的创新疗法。